Pfizer's stock has declined nearly 20% over five years, pushing its dividend yield to around 6%. Despite this, the company continues to pay a steady $0.43 quarterly dividend, supported by earnings that cover the payout but with tight cash flow margins. CEO Albert Bourla has committed to maintaining the dividend through upcoming challenges, including a $1.5 billion loss-of-exclusivity impact in 2026, though significant dividend hikes are unlikely until growth resumes. Investors face a mixed picture: an attractive yield driven by price weakness, solid earnings coverage, but limited buybacks and tight cash flow.
Moderna's stock dropped 25% after a late-stage melanoma vaccine report was briefly posted online and then removed. The vaccine, developed with Merck, showed favorable results in reducing melanoma recurrence or death when combined with Keytruda, but t...
Pfizer offers a high 5.7% dividend yield compared to Merck's 2.2%, but Pfizer's dividend payout exceeds its free cash flow, signaling risk. Merck's dividend is covered comfortably by free cash flow and has grown steadily since 2020, making it a safer...
Moderna's stock surged 7% as investors anticipate the release of late-stage melanoma vaccine data at the European Society for Medical Oncology congress in Madrid on October 24. The data involves a combination of Moderna's intismeran autogene and Merc...
Five companies—Coca-Cola, Colgate-Palmolive, AT&T, Dominion Energy, and Pfizer—offer dividend stocks that provide steady income with less market volatility, ideal for investors seeking stability. These companies sell essential products or services th...
Five well-known dividend stocks—Kraft Heinz, Pfizer, Dow Inc., Verizon, and AT&T—are showing warning signs that their high dividend yields may not be sustainable. Issues include earnings and cash flow shortfalls, rising debt, and dividend payouts exc...
